Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Forum: Aktien User: Coronaprofiteur

Beim Erbrechen nimmt man ja auch quasi ab!

Schon recht hohe rate bei übelkeit Durchfall und erbrechen

The most common adverse events among participants treated with retatrutide (4 mg, 9 mg, 12 mg, vs. placebo, respectively) were nausea (28.6%, 38.4% and 42.4% vs. 14.8%), diarrhea (25.2%, 34.1% and 32.0% vs. 13.5%), constipation (23.8%, 25.9% and 26.1% vs. 10.9%), vomiting (10.6%, 22.8% and 25.3% vs. 4.8%), and upper respiratory tract infection (14.2%, 12.2% and 13.1% vs. 11.6%). Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo. Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide. Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo.

die Retatrutide-Daten zwingen Novo dazu, bei der eigenen Forschung und Entwicklung (insbesondere bei CagriSema) fehlerfrei abzuliefern, um nicht die technologische Marktführerschaft dauerhaft an Eli Lilly zu verlieren.

Uff das ist mal wieder eine Ansage von Eli Lilly

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Eli Lilly’s Retatrutide Shows Up to 𝟑𝟎.𝟑% Weight Loss in Phase 3 Trial - $LLY $NVO $HIMS 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ Lilly’s 𝐫𝐞𝐭𝐚𝐭𝐫𝐮𝐭𝐢𝐝𝐞 achieved up to 𝟐𝟖.𝟑% weight loss over 𝟖𝟎 weeks. ➤ Highest 𝟏𝟐 𝐦𝐠 dose delivered average loss of 𝟕𝟎.𝟑 pounds. ➤ 𝟒𝟓.𝟑% of participants lost 𝟑𝟎% or more body weight. ➤ Extension study showed up to 𝟑𝟎.𝟑% weight loss after 𝟏𝟎𝟒 weeks. ➤ 𝟔𝟓.𝟑% of patients on 𝟏𝟐 𝐦𝐠 moved below obesity-level BMI. ➤ Common side effects included 𝐧𝐚𝐮𝐬𝐞𝐚, diarrhea, constipation, and vomiting. ➤ Retatrutide targets 𝐆𝐈𝐏, 𝐆𝐋𝐏-𝟏, and glucagon hormone receptors.

Das war vor über 15 Minuten

Ich habe nachgekauft

Enorme Vola jetzt, 1€ Schwankung binnen Sekunden. 🧐

Iran hat gesprochen

Fällt

Crazy😅

Was ist grade passiert?

Hier 🙋. Warte auf die EMA Meldung ...

Wo ist mein Freund CSl?

The most bearish analyst on $NVO just raised their target. Quietly. While keeping the negative rating to save face. Bernstein: DKK 175 to DKK 200. Up 14%. Still rated Underperform. This is how bearish capitulation begins. The analyst who was most negative blinks first, raises the number, but keeps the label to avoid admitting the thesis is changing. Worth remembering: Bernstein hosts Lilly's Strategic Decisions Conference. Same firm. And even they just moved their Novo floor up 14%. When the most conflicted bear on the street raises their target, the floor of the estimate range moves with them. DKK 175 is gone. DKK 200 is the new bottom. Meanwhile the stock trades at DKK 283, Novo buys back 200,000 shares a day at DKK 290-302, and the CHMP opinion on the European oral monopoly lands any day now. The narrative updates last. But it's starting to update. $NVO $LLY $VKTX